Home » Drug Information » FDA Approved Drugs » 1997
Medical Areas: Endocrinology | Family Medicine
View By:YearCompanyConditionsTherapeutic AreasDrug Names
The following drug information is obtained from various newswires, published
medical journal articles, and medical conference presentations.
Company: Novo Nordisk
Approval Status: Approved December 1997
Treatment Area: Type II diabetes
Prandin (repaglinide) has been approved for the treatment of
Type 2 diabetes. It is the first approved product in a new chemical
class (meglitinide class) of orally administered drugs for the
treatment of Type 2 diabetes, and was developed to manage meal
related (prandial) glucose loads.
In clinical trials, Prandin had its largest effect in the first
two weeks. After that, patients were maintained at a dose that
triggered response. There was an average reduction in hemoglobin
A1c levels of 1.6 to 1.9 points.
Adverse events reported were comparable to sulfonylureas, but
there was a slightly higher incidence of cardiovascular events when
compared with glyburide.
Mechanism of Action
Prandin stimulates insulin secretion from the beta cells of the
pancreas by binding to sites on the beta cell. Its quick onset and
short duration of action concentrates its effect around meal time
glucose load, which is important to the treatment of Type 2
diabetes. Prandin is minimally excreted by the kidney, which may be
an advantage for patients who suffer from decreased kidney